{"id":44985,"date":"2022-06-13T09:01:34","date_gmt":"2022-06-13T07:01:34","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\/"},"modified":"2022-06-13T09:01:34","modified_gmt":"2022-06-13T07:01:34","slug":"bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\/","title":{"rendered":"Bryan Garnier & Co Initiates the Coverage of Median Technologies with a \u201cBuy\u201d Recommendation"},"content":{"rendered":"
\n

SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory News:\n<\/p>\n

<\/a><\/p>\n

\nMedian Technologies (ALMDT) announces today the publication of an initiation report by Bryan Garnier & Co, a pan-European investment bank focusing on growth companies.\n<\/p>\n

\nIn the initiation report published on June 10, 2022, Bryan Garnier & Co initiates the coverage of the stock with a buy recommendation and values the company at 40 euros per share.\n<\/p>\n

\nAbout Bryan Garnier & Co: <\/b>Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Stockholm, Oslo and Reykjavik as well as New York and Palo Alto. The firm is a member of the London Stock Exchange.\n<\/p>\n

\nFor more information: www.bryangarnier.com<\/a>\n<\/p>\n

\nAbout Median Technologies:<\/strong> <\/b>Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy\u00ae, our AI-powered software as medical device help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.\n<\/p>\n

\nFounded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label \u201cInnovative company\u201d by the BPI and is listed on Euronext Growth market (Paris). FR0011049824\u2013 ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME), is part of the Enternext\u00ae PEA-PME 150 index and has been awarded the Euronext European Rising Tech label. For more information: www.mediantechnologies.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedian Technologies<\/b>
Emmanuelle Leygues
\n
Head of Corporate Marketing & Financial Communications
\n
+33 6 10 93 58 88
\n
emmanuelle.leygues@mediantechnologies.com<\/a>\n<\/p>\n

\nPress – ALIZE RP<\/b>
Caroline Carmagnol
\n
+33 6 64 18 99 59
\n
median@alizerp.com<\/a>\n<\/p>\n

\nInvestors – ACTIFIN<\/b>
Ghislaine Gasparetto
\n
+33 6 21 10 49 24
\n
ggasparetto@actifin.fr<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory News: Median Technologies (ALMDT) announces today the publication of an initiation report by Bryan Garnier & Co, a pan-European investment bank focusing on growth companies. In the initiation report published on June 10, 2022, Bryan Garnier & Co initiates the coverage of the stock with a buy recommendation and values the … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-44985","format-standard","category-industry"],"yoast_head":"\nBryan Garnier & Co Initiates the Coverage of Median Technologies with a \u201cBuy\u201d Recommendation - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bryan Garnier & Co Initiates the Coverage of Median Technologies with a \u201cBuy\u201d Recommendation - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory News: Median Technologies (ALMDT) announces today the publication of an initiation report by Bryan Garnier & Co, a pan-European investment bank focusing on growth companies. In the initiation report published on June 10, 2022, Bryan Garnier & Co initiates the coverage of the stock with a buy recommendation and values the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-13T07:01:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220612005016\/en\/1343975\/21\/Median_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Bryan Garnier & Co Initiates the Coverage of Median Technologies with a \u201cBuy\u201d Recommendation\",\"datePublished\":\"2022-06-13T07:01:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\\\/\"},\"wordCount\":413,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220612005016\\\/en\\\/1343975\\\/21\\\/Median_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\\\/\",\"name\":\"Bryan Garnier & Co Initiates the Coverage of Median Technologies with a \u201cBuy\u201d Recommendation - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220612005016\\\/en\\\/1343975\\\/21\\\/Median_RGB.jpg\",\"datePublished\":\"2022-06-13T07:01:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220612005016\\\/en\\\/1343975\\\/21\\\/Median_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220612005016\\\/en\\\/1343975\\\/21\\\/Median_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bryan Garnier & Co Initiates the Coverage of Median Technologies with a \u201cBuy\u201d Recommendation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bryan Garnier & Co Initiates the Coverage of Median Technologies with a \u201cBuy\u201d Recommendation - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\/","og_locale":"en_US","og_type":"article","og_title":"Bryan Garnier & Co Initiates the Coverage of Median Technologies with a \u201cBuy\u201d Recommendation - Pharma Trend","og_description":"SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory News: Median Technologies (ALMDT) announces today the publication of an initiation report by Bryan Garnier & Co, a pan-European investment bank focusing on growth companies. In the initiation report published on June 10, 2022, Bryan Garnier & Co initiates the coverage of the stock with a buy recommendation and values the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-13T07:01:34+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220612005016\/en\/1343975\/21\/Median_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Bryan Garnier & Co Initiates the Coverage of Median Technologies with a \u201cBuy\u201d Recommendation","datePublished":"2022-06-13T07:01:34+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\/"},"wordCount":413,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220612005016\/en\/1343975\/21\/Median_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\/","url":"https:\/\/pharma-trend.com\/en\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\/","name":"Bryan Garnier & Co Initiates the Coverage of Median Technologies with a \u201cBuy\u201d Recommendation - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220612005016\/en\/1343975\/21\/Median_RGB.jpg","datePublished":"2022-06-13T07:01:34+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220612005016\/en\/1343975\/21\/Median_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220612005016\/en\/1343975\/21\/Median_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/bryan-garnier-co-initiates-the-coverage-of-median-technologies-with-a-buy-recommendation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Bryan Garnier & Co Initiates the Coverage of Median Technologies with a \u201cBuy\u201d Recommendation"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44985","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44985"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44985\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}